1) Cancer Genome Atlas Research Network, et al : Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965, 2017
2) Cancer Genome Atlas Research Network : Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 : 43-49, 2013
3) Cancer Genome Atlas Research Network : The Molecular Taxonomy of Primary Prostate Cancer. Cell 163 : 1011-1025, 2015
4) Cancer Genome Atlas Research Network : Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 : 315-322, 2014
5) Gounder MM, et al : Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nat Commun 13 : 3406, 2022
6) Tawbi HA, et al : Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18 : 1493-1501, 2017
7) Lee ATJ, et al : Clinical and Molecular Spectrum of Liposarcoma. J Clin Oncol 36 : 151-159, 2018
8) Amer KM, et al : Epidemiology and survival of liposarcoma and its subtypes : A dual database analysis. J Clin Orthop Trauma 11 : S479-S484, 2020
9) Assi T, et al : Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma : A comprehensive review. Crit Rev Oncol Hematol 153 : 103029, 2020
10) Gounder MM, et al : A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol 41 : 1714-1724, 2023
11) Schöffski P, et al : Brightline-1 : phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Future Oncol 19 : 621-629, 2023